Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Moreover, BCMA (B-cell maturation antigen) has consolidated as the most clinically valuable target in multiple myeloma immunotherapy, with 164 active drug programs, 1,793 patent filings since January 2023, and 174 ongoing Phase 2 and Phase 3 trials. Notably, the field is anchored by six approved products: Bristol Myers Squibb / 2seventy bio’s Abecma (Idecabtagene vicleucel), Janssen / Legend Biotech’s Carvykti (Ciltacabtagene autoleucel), GSK’s Blenrep (Belantamab mafodotin) re-approved in 2025, Janssen’s…
Author: Eureka LS
Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Moreover, pyrotinib Maleate (商品名艾瑞妮 / Aritine) is an irreversible small-molecule pan-HER receptor tyrosine kinase inhibitor developed by Jiangsu Hengrui Pharmaceuticals, originally approved by China’s NMPA in August 2018 for HER2-positive metastatic breast cancer. Notably, the molecule has expanded into one of the most clinically active HER2 TKIs globally, with 295 ongoing trials, 14 patent filings since January 2023 covering formulation, combination, and process improvements, and 6 disclosed business development deals.…
Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Moreover, systemic Lupus Erythematosus (SLE) has been transformed from a uniformly chronic biologic-dependent disease into the proving ground for autoimmune CAR-T cell therapy, with 724 active drug programs, 3,703 patent filings since January 2023, and 471 ongoing Phase 2 and Phase 3 trials. Notably, 2024-2026 produced a series of approvals including Anbalcabtagene autoleucel (April 2026), Puzolcabtagene autoleucel (November 2025), Obecabatagene autoleucel (November 2024), Inaticabtagene Autoleucel (2023-11), Obinutuzumab β anti-CD20 mAb…
Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Moreover, PROTAC (proteolysis-targeting chimera) therapeutics have crossed the regulatory finish line in 2026, with Arvinas / Pfizer’s Vepdegestrant becoming the first FDA-approved PROTAC drug on May 1, 2026. Notably, the broader landscape now includes 3,620 active PROTAC drug programs in the Patsnap Eureka database, 594 PROTAC-specific patent filings since January 2023, and 35 ongoing Phase 2 and Phase 3 PROTAC trials. Specifically, the late-stage clinical pipeline is led by Arvinas…
Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Moreover, jiangsu Hengrui Pharmaceuticals has consolidated as China’s most prolific innovative drug developer, with 427 active drug programs, 630 ongoing Phase 2 and Phase 3 trials, and 28 disclosed business development deals captured in the Patsnap Eureka database. Notably, the company holds 25+ approved drugs across oncology, cardiometabolic, autoimmune, anesthesia, and ophthalmology indications — making it the broadest portfolio Chinese pharma globally. Specifically, Hengrui’s 2024-2026 commercial momentum has been driven…
Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Moreover, autoimmune diseases collectively represent the second-largest therapeutic area after oncology, with 5,533 active drug programs across the disease cluster, 11,570 patent filings since January 2023, and over a million ongoing clinical trials when aggregated across the major indications (lupus, rheumatoid arthritis, multiple sclerosis, psoriasis, IBD, myasthenia gravis, and others). Notably, 2025-2026 produced a transformational regulatory wave: Anbalcabtagene autoleucel and Puzolcabtagene Autoleucel — the first CAR-T therapies approved for autoimmune…
Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Moreover, inflammatory Bowel Diseases (IBD) — covering ulcerative colitis (UC) and Crohn’s disease (CD) — anchor 1,837 active drug programs, 7,198 patent filings since January 2023, and 1,244 ongoing Phase 2 and Phase 3 trials. Notably, 2025-2026 has produced an exceptional wave of approvals including Janssen’s oral peptide IL-23 antagonist Icotrokinra (March 2026), Lilly’s Mirikizumab (Omvoh) for Crohn’s expansion, and multiple Chinese-developed JAK and IL-23 mAb approvals. Specifically, the late-stage…
Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Moreover, psoriasis has matured into one of the most commercially valuable autoimmune indications, anchoring 1,241 active drug programs, 5,122 patent filings since January 2023, and 1,280 ongoing Phase 2 and Phase 3 trials. Notably, the recent approval of Janssen’s Icotrokinra in March 2026 marks the first oral peptide IL-23 antagonist, expanding the modality landscape beyond injectable biologics. Specifically, the late-stage competitive frontier is dominated by IL-17 and IL-23 biologics —…
Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Moreover, STING1 (also known as TMEM173 or stimulator of interferon genes) has consolidated as one of the most heavily explored innate immunity targets in oncology, with 200 active drug programs, 1,312 patent filings since January 2023, and 13 ongoing Phase 2 and Phase 3 trials. Notably, despite over a decade of investment, no STING1 modulator has yet received regulatory approval, leaving the entire field in pre-commercial competitive positioning. Specifically, the…
Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Moreover, CTLA4 has remained one of the most strategically central immune-oncology targets since Bristol Myers Squibb’s Ipilimumab approval in 2011, and the 2026 landscape shows the field has decisively shifted from monotherapy mAbs to multi-specific formats. Notably, the database contains 182 active drug programs, 3,829 patent filings since January 2023, and 1,137 ongoing Phase 2 and Phase 3 trials. Specifically, the modality mix has tilted: 49 monoclonal antibodies coexist with…